100 related articles for article (PubMed ID: 12673200)
1. Delineation of the domains required for physical and functional interaction of p14ARF with human topoisomerase I.
Ayrault O; Karayan L; Riou JF; Larsen CJ; Séité P
Oncogene; 2003 Apr; 22(13):1945-54. PubMed ID: 12673200
[TBL] [Abstract][Full Text] [Related]
2. Human ARF protein interacts with topoisomerase I and stimulates its activity.
Karayan L; Riou JF; Séité P; Migeon J; Cantereau A; Larsen CJ
Oncogene; 2001 Feb; 20(7):836-48. PubMed ID: 11314011
[TBL] [Abstract][Full Text] [Related]
3. p14ARF interacts with N-Myc and inhibits its transcriptional activity.
Amente S; Gargano B; Diolaiti D; Della Valle G; Lania L; Majello B
FEBS Lett; 2007 Mar; 581(5):821-5. PubMed ID: 17289033
[TBL] [Abstract][Full Text] [Related]
4. Detailed computational study of p53 and p16: using evolutionary sequence analysis and disease-associated mutations to predict the functional consequences of allelic variants.
Greenblatt MS; Beaudet JG; Gump JR; Godin KS; Trombley L; Koh J; Bond JP
Oncogene; 2003 Feb; 22(8):1150-63. PubMed ID: 12606942
[TBL] [Abstract][Full Text] [Related]
5. Immunolocalization of human p14(ARF) to the granular component of the interphase nucleolus.
Lindström MS; Klangby U; Inoue R; Pisa P; Wiman KG; Asker CE
Exp Cell Res; 2000 May; 256(2):400-10. PubMed ID: 10772813
[TBL] [Abstract][Full Text] [Related]
6. Human Arf tumor suppressor specifically interacts with chromatin containing the promoter of rRNA genes.
Ayrault O; Andrique L; Larsen CJ; Seite P
Oncogene; 2004 Oct; 23(49):8097-104. PubMed ID: 15361825
[TBL] [Abstract][Full Text] [Related]
7. Defining the molecular basis of Arf and Hdm2 interactions.
Bothner B; Lewis WS; DiGiammarino EL; Weber JD; Bothner SJ; Kriwacki RW
J Mol Biol; 2001 Nov; 314(2):263-77. PubMed ID: 11718560
[TBL] [Abstract][Full Text] [Related]
8. Simian virus 40 large T antigen binds to topoisomerase I.
Simmons DT; Melendy T; Usher D; Stillman B
Virology; 1996 Aug; 222(2):365-74. PubMed ID: 8806520
[TBL] [Abstract][Full Text] [Related]
9. RRM proteins interacting with the cap region of topoisomerase I.
Trzcińska-Daneluti AM; Górecki A; Czubaty A; Kowalska-Loth B; Girstun A; Murawska M; Lesyng B; Staroń K
J Mol Biol; 2007 Jun; 369(4):1098-112. PubMed ID: 17481653
[TBL] [Abstract][Full Text] [Related]
10. CDKN2A point mutations D153spl(c.457G>T) and IVS2+1G>T result in aberrant splice products affecting both p16INK4a and p14ARF.
Rutter JL; Goldstein AM; Dávila MR; Tucker MA; Struewing JP
Oncogene; 2003 Jul; 22(28):4444-8. PubMed ID: 12853981
[TBL] [Abstract][Full Text] [Related]
11. The p14ARF alternate reading frame protein enhances DNA binding of topoisomerase I by interacting with the serine 506-phosphorylated core domain.
Bandyopadhyay K; Li P; Gjerset RA
PLoS One; 2013; 8(3):e58835. PubMed ID: 23555599
[TBL] [Abstract][Full Text] [Related]
12. Frequent alteration of p16(INK4a)/p14(ARF) and p53 pathways in the round cell component of myxoid/round cell liposarcoma: p53 gene alterations and reduced p14(ARF) expression both correlate with poor prognosis.
Oda Y; Yamamoto H; Takahira T; Kobayashi C; Kawaguchi K; Tateishi N; Nozuka Y; Tamiya S; Tanaka K; Matsuda S; Yokoyama R; Iwamoto Y; Tsuneyoshi M
J Pathol; 2005 Dec; 207(4):410-21. PubMed ID: 16177957
[TBL] [Abstract][Full Text] [Related]
13. A dose-dependent tug of war involving the NPM1 leukaemic mutant, nucleophosmin, and ARF.
Bolli N; De Marco MF; Martelli MP; Bigerna B; Pucciarini A; Rossi R; Mannucci R; Manes N; Pettirossi V; Pileri SA; Nicoletti I; Falini B
Leukemia; 2009 Mar; 23(3):501-9. PubMed ID: 19005479
[TBL] [Abstract][Full Text] [Related]
14. Raman and CD spectroscopy of recombinant 68-kDa DNA human topoisomerase I and its complex with suicide DNA-substrate.
Fleury F; Ianoul A; Kryukov E; Sukhanova A; Kudelina I; Wynne-Jones A; Bronstein IB; Maizieres M; Berjot M; Dodson GG; Wilkinson AJ; Holden JA; Feofanov AV; Alix AJ; Jardillier JC; Nabiev I
Biochemistry; 1998 Oct; 37(41):14630-42. PubMed ID: 9772192
[TBL] [Abstract][Full Text] [Related]
15. Alteration of the p14(ARF) gene and p53 status in human hepatocellular carcinomas.
Ito T; Nishida N; Fukuda Y; Nishimura T; Komeda T; Nakao K
J Gastroenterol; 2004; 39(4):355-61. PubMed ID: 15168247
[TBL] [Abstract][Full Text] [Related]
16. Relationship between alterations of p16(INK4a) and p14(ARF) genes of CDKN2A locus and gastric carcinogenesis.
Tang S; Luo H; Yu J; Yang D; Shu J
Chin Med J (Engl); 2003 Jul; 116(7):1083-7. PubMed ID: 12890389
[TBL] [Abstract][Full Text] [Related]
17. Genomic instability, mutations and expression analysis of the tumour suppressor genes p14(ARF), p15(INK4b), p16(INK4a) and p53 in actinic keratosis.
Kanellou P; Zaravinos A; Zioga M; Stratigos A; Baritaki S; Soufla G; Zoras O; Spandidos DA
Cancer Lett; 2008 Jun; 264(1):145-61. PubMed ID: 18331779
[TBL] [Abstract][Full Text] [Related]
18. Loss of p21 disrupts p14 ARF-induced G1 cell cycle arrest but augments p14 ARF-induced apoptosis in human carcinoma cells.
Hemmati PG; Normand G; Verdoodt B; von Haefen C; Hasenjäger A; Güner D; Wendt J; Dörken B; Daniel PT
Oncogene; 2005 Jun; 24(25):4114-28. PubMed ID: 15750619
[TBL] [Abstract][Full Text] [Related]
19. The ARF tumor suppressor inhibits BCL6-mediated transcriptional repression.
Suzuki H; Kurita M; Mizumoto K; Moriyama M; Aiso S; Nishimoto I; Matsuoka M
Biochem Biophys Res Commun; 2005 Jan; 326(1):242-8. PubMed ID: 15567177
[TBL] [Abstract][Full Text] [Related]
20. Apoptosis induced by adenovirus-mediated p14ARF expression in U2OS osteosarcoma cells is associated with increased Fas expression.
Kim M; Sgagias M; Deng X; Jung YJ; Rikiyama T; Lee K; Ouellette M; Cowan K
Biochem Biophys Res Commun; 2004 Jul; 320(1):138-44. PubMed ID: 15207713
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
